Abstract
Background The emergence of the coronavirus disease 2019 (COVID-19) pandemic in March 2020 created unprecedented challenges in the provision of scheduled ambulatory cancer care. As a result, there has been a renewed focus on video consultations as a means to continue ambulatory care.
Objective To characterize the increase in video visits at the University of California, San Francisco Comprehensive Cancer Center in response to COVID-19 and compare demographics/appointment data from January 1, 2020 and in the 3 weeks after transition to video visits.
Methods Demographics and appointment data (dates, visit types, and departments) were abstracted from the Electronic Health Record reporting database. Video visits were performed using a HIPAA-compliant video conferencing platform with a pre-existing workflow.
Results In 17 departments and divisions at the Cancer Center, 2,284 video visits were performed in the pre-COVID-19 period (average 208 ± 75 per week) and 3,015 performed in the 3-week post-COVID-19 period (average 1,005 ± 149 per week). The proportion of video visits increased from 7-18% to 54-68%, between the pre- and post-COVID-19 periods without any disparity based on race/ethnicity, primary language, or insurance
Conclusions In a remarkably brief period of time, we rapidly scaled the utilization of telehealth in response to COVID-19 and maintained access to complex oncologic care at a time of social distancing.
Competing Interest Statement
Dr. Odisho was a consultant for VSee from December 2019 to January 2020.
Funding Statement
None
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
On request
